Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 5/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | TLR4 | O00206 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CPB1 | P15086 | 2/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18623681 | 1.00 | ALDH1A1 (0.67) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL5493045 | 0.92 | ALDH1A1 (0.74) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL5493043 | 0.92 | ALDH1A1 (0.74) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL19408982 | 0.89 | ALDH1A1 (0.70) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL381922 | 0.87 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3948456 | 0.87 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL3948461 | 0.87 | ALDH1A1 (0.85) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL28672916 | 0.85 | ALDH1A1 (0.62) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL30151806 | 0.85 | ALDH1A1 (0.62) | ALDH1A1GAATSHREPHX1DPP4 | |
| SCHEMBL26342515 | 0.85 | ALDH1A1 (0.62) | ALDH1A1GAATSHREPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350178-B1 | NOVEL IMIDAZO [4,5-C]QUINOLINE AND IMIDAZO [4,5-C][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-10-20 | — | — | EP | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017046675-A1 | NOVEL IMIDAZO [4,5-C] QUINOLINE AND IMIDAZO [4,5-C][1,5] NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073343-A1 | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | LRRK2, PARK7, SNCA | ALDH1A1 1764/4885GAA 376/4885TSHR 1893/4885 |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | ALDH1A1 1623/4885GAA 3764/4885TSHR 220/4885 |
| US-10039753-B2 | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | LRRK2, PARK7, SNCA | ALDH1A1 1603/4885GAA 270/4885TSHR 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.